侵襲性線維腫症市場：治療タイプ、流通チャネル、エンドユーザー別-2025-2030年の世界予測

侵襲性線維腫症市場は、2023年に27億4,000万米ドルと評価され、2024年には29億米ドルに達すると予測され、CAGR 5.88％で成長し、2030年には41億米ドルになると予測されています。

侵襲性線維腫症は、デスモイド腫瘍としても知られ、筋・腱膜構造から発生し転移しないまれなタイプの局所浸潤性腫瘍です。侵襲性線維腫症の市場範囲は主に、外科的介入、薬理学的治療、標的治療や免疫療法などの先進的治療アプローチに重点を置いた、効果的な治療法の開拓、応用、商品化を中心に展開されています。この疾患は、術後の再発や有効な薬物療法が限られていることから、臨床上の課題となっています。新しい治療レジメンの必要性は、特に、過剰な副作用なしに再発を予防し、罹患率を管理する必要性に起因しています。最終用途の範囲は主に、患者が診断と治療を求める病院、専門クリニック、がん治療センターを対象としています。この市場の主な成長促進要因としては、疾患に対する意識の高まり、画像診断技術の発展、より効果的な治療法の研究開発への関心の高まりなどが挙げられます。非侵襲的な治療法の開発、アンメット・メディカル・ニーズのある新興国市場への進出、バイオテクノロジーを活用した革新的なドラッグ・デリバリー・システムなどに潜在的なビジネスチャンスがあります。とはいえ、治療費の高騰、市場規模を制限する可能性のある疾患の希少性、新規参入企業にとって課題となる規制上のハードルなどの制約があります。希少疾病の調査に対する資金調達の制約は、さらに成長見通しに影響を与えます。技術革新と事業成長のためには、分子遺伝学の的を絞った調査、新薬製剤のための確固とした臨床試験、世界的機関同士の知識共有のための共同研究が、実行可能な道筋を提供します。市場はニッチではあるが、がん研究の技術的進歩や希少疾病用医薬品の研究開発への戦略的注力が成長の原動力となっています。要するに、研究への大幅な投資と、教育や患者支援への戦略的な注力とが相まって、市場のダイナミクスが大幅に強化される可能性があります。

市場力学：急速に進化する侵襲性線維腫症市場の主要市場インサイトを公開

侵襲性線維腫症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ヘルスケア提供者の意識の高まりと侵襲性線維腫症の診断精度の向上
  • 希少疾患の治療開発を促進する規制支援と希少疾病用医薬品の指定
  • 新たな治療法の開発を加速するための製薬企業、研究機関、学術センター間の連携とパートナーシップの拡大
• 市場抑制要因
  • 特にニッチな疾患に対する新たな治療法の開発と市場導入に要する研究開発コストの高さ
• 市場機会
  • 侵襲性線維腫症の遺伝的・分子的基盤に関する医学研究と技術の進歩
  • 治療反応や患者のアドヒアランスをモニタリングするための遠隔医療、モバイルヘルスアプリ、ウェアラブルデバイスなどのデジタルヘルス技術の統合
• 市場の課題
  • 侵襲性線維腫症に対する治療選択肢と標的治療が限られていること

ポーターの5つの力：侵襲性線維腫症市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、侵襲性線維腫症市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：侵襲性線維腫症市場における外部からの影響の把握

外部マクロ環境要因は、侵襲性線維腫症市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析侵襲性線維腫症市場における競合情勢の把握

侵襲性線維腫症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス侵襲性線維腫症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、侵襲性線維腫症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨侵襲性線維腫症市場における成功への道筋を描く

侵襲性線維腫症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ヘルスケア従事者の意識の高まりと侵襲性線維腫症のより正確な診断
    • 希少疾患の治療法開発を促進する規制支援と希少疾病用医薬品の指定
    • 製薬会社、調査機関、学術センター間の協力とパートナーシップの拡大により、新たな治療法の開発が加速
  • 抑制要因
    • 特にニッチな疾患に対する新しい治療法を開発し市場に投入するには、高い研究開発費が必要である
  • 機会
    • 侵襲性線維腫症の遺伝的および分子的基礎に関する医学調査と技術の進歩
    • 遠隔医療、モバイルヘルスアプリ、治療反応や患者の遵守状況をモニタリングするためのウェアラブルデバイスなどのデジタルヘルス技術の統合
  • 課題
    • 侵襲性線維腫症に対する治療選択肢と標的療法は限られている
• 市場セグメンテーション分析
  • 治療の種類：低侵襲性のため、非外科的治療が好まれる傾向が高まっている
  • エンドユーザー：低侵襲手術を提供する外来手術センターのニーズが高まっている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 侵襲性線維腫症市場治療の種類別

• 非外科的治療
  • 凍結療法
  • 薬物療法
  • 放射線治療
  • 高周波アブレーション
• 外科的治療
  • 保存的手術
  • 根治切除

第7章 侵襲性線維腫症市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 侵襲性線維腫症市場：エンドユーザー別

• 外来手術センター
• 病院
• 調査・学術機関
• 専門クリニック

第9章 南北アメリカの侵襲性線維腫症市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の侵襲性線維腫症市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの侵襲性線維腫症市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 欧州医薬品庁は、第3相DeFi試験の結果を受けて、デスモイド腫瘍の画期的な治療であるニロガセスタットに対するスプリングワークス・セラピューティクスの申請を承認しました。
  • SpringWorks Therapeuticsのニロガセスタット MAAがEMAに承認され、デスモイド腫瘍に対する初のEU承認治療法への道が開かれ、第3相試験の結果から大きな臨床的利点が示されました。
  • イミュノーム社は、がん治療ポートフォリオと臨床成果を強化するために、アヤラ社から第3相ガンマセクレターゼ阻害剤AL102を5,000万米ドルで買収しました。
• 戦略分析と提言

企業一覧

• 4D Molecular Therapeutics
• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Aurinia Pharmaceuticals Inc.
• Bayer AG
• Bioporto Diagnostics A/S
• Boston Scientific Corporation
• Celgene Corporation（a Bristol-Myers Squibb Company）
• Eli Lilly and Company
• Epizyme, Inc.
• Exelixis, Inc.
• GlaxoSmithKline plc
• Hoffmann-La Roche Ltd.
• Infinity Pharmaceuticals, Inc.
• Johnson & Johnson Service, Inc.
• Medtronic plc
• Merck & Co., Inc.
• Novartis AG
• Oncoheroes Biosciences Inc.
• Pfizer Inc.
• Sanofi S.A.
• SpringWorks Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. AGGRESSIVE FIBROMATOSIS MARKET RESEARCH PROCESS
• FIGURE 2. AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AGGRESSIVE FIBROMATOSIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. AGGRESSIVE FIBROMATOSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AGGRESSIVE FIBROMATOSIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AGGRESSIVE FIBROMATOSIS MARKET DYNAMICS
• TABLE 7. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY CRYOABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY CONSERVATIVE SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RADICAL RESECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 45. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. CANADA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. CHINA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. INDIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 163. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 164. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. ITALY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 181. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 185. POLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 186. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 188. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 190. QATAR AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY NON-SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY SURGICAL TREATMENT, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM AGGRESSIVE FIBROMATOSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 236. AGGRESSIVE FIBROMATOSIS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. AGGRESSIVE FIBROMATOSIS MARKET, FPNV POSITIONING MATRIX, 2023

The Aggressive Fibromatosis Market was valued at USD 2.74 billion in 2023, expected to reach USD 2.90 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 4.10 billion by 2030.

Aggressive fibromatosis, also known as desmoid tumors, is a rare type of locally invasive tumor which arises from the musculo-aponeurotic structures and does not metastasize. The market scope for aggressive fibromatosis primarily revolves around the development, application, and commercialization of effective therapies, emphasizing surgical interventions, pharmacological treatments, and advanced therapeutic approaches such as targeted therapy and immunotherapy. This condition notoriously poses a clinical challenge given its recurrence post-surgery and limited effective pharmacotherapy. The necessity for novel treatment regimens can be particularly attributed to the need to prevent recurrence and manage morbidity without excessive adverse effects. The end-use scope primarily targets hospitals, specialty clinics, and cancer treatment centers where patients seek diagnosis and treatment. Key growth drivers in this market include heightened awareness about the condition, advancements in diagnostic imaging techniques, and the increasing interest in research and development for more effective therapeutic methods. Potential opportunities lie in developing non-invasive therapies, expanding into emerging markets with unmet medical needs, and leveraging biotechnology for innovative drug delivery systems. Nonetheless, the market faces limitations such as high treatment costs, the rarity of the condition which may limit market size, and regulatory hurdles which pose challenges to new market entrants. Funding constraints for research into rare diseases further impact growth prospects. For innovation and business growth, targeted research in molecular genetics, robust clinical trials for novel drug formulations, and collaborations for knowledge sharing among global institutions offer viable pathways. The market is largely niche but poised for growth driven by technological advances in oncology research and a strategic focus on orphan drug development. In essence, substantial investment in research, coupled with a strategic focus on education and patient advocacy, could significantly enhance market dynamics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Aggressive Fibromatosis Market

The Aggressive Fibromatosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
  • Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
  • Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
• Market Restraints
  • High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
• Market Opportunities
  • Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
  • Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
• Market Challenges
  • Limited treatment options and targeted therapies for aggressive fibromatosis

Porter's Five Forces: A Strategic Tool for Navigating the Aggressive Fibromatosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Aggressive Fibromatosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Aggressive Fibromatosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Aggressive Fibromatosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Aggressive Fibromatosis Market

A detailed market share analysis in the Aggressive Fibromatosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Aggressive Fibromatosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Aggressive Fibromatosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Aggressive Fibromatosis Market

A strategic analysis of the Aggressive Fibromatosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Aggressive Fibromatosis Market, highlighting leading vendors and their innovative profiles. These include 4D Molecular Therapeutics, AbbVie Inc., Amgen Inc., AstraZeneca plc, Aurinia Pharmaceuticals Inc., Bayer AG, Bioporto Diagnostics A/S, Boston Scientific Corporation, Celgene Corporation (a Bristol-Myers Squibb Company), Eli Lilly and Company, Epizyme, Inc., Exelixis, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Infinity Pharmaceuticals, Inc., Johnson & Johnson Service, Inc., Medtronic plc, Merck & Co., Inc., Novartis AG, Oncoheroes Biosciences Inc., Pfizer Inc., Sanofi S.A., SpringWorks Therapeutics, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Aggressive Fibromatosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Non-Surgical Treatment and Surgical Treatment. The Non-Surgical Treatment is further studied across Cryoablation, Pharmacological Therapies, Radiation Therapy, and Radiofrequency Ablation. The Surgical Treatment is further studied across Conservative surgery and Radical resection.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, Research & Academic Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising awareness among healthcare providers and more accurate diagnosis of aggressive fibromatosis
    • 5.1.1.2. Regulatory support and orphan drug designations encouraging the development of treatments for rare diseases
    • 5.1.1.3. Growing collaboration and partnerships between pharmaceutical companies, research institutions, and academic centers to accelerate the development of new treatments
  • 5.1.2. Restraints
    • 5.1.2.1. High R&D Costs required to develop and bring new therapies to market particularly for niche conditions
  • 5.1.3. Opportunities
    • 5.1.3.1. Advances in medical research and technology of the genetic and molecular basis of aggressive fibromatosis
    • 5.1.3.2. Integration in digital health technologies such as telemedicine, mobile health apps, and wearable devices for monitoring treatment response and patient adherence
  • 5.1.4. Challenges
    • 5.1.4.1. Limited treatment options and targeted therapies for aggressive fibromatosis
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Growing preference for non-surgical treatments owing to their minimally invasive nature
  • 5.2.2. End User: Increasing need for ambulatory surgical centers offering minimally invasive surgical interventions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Aggressive Fibromatosis Market, by Treatment Type

• 6.1. Introduction
• 6.2. Non-Surgical Treatment
  • 6.2.1. Cryoablation
  • 6.2.2. Pharmacological Therapies
  • 6.2.3. Radiation Therapy
  • 6.2.4. Radiofrequency Ablation
• 6.3. Surgical Treatment
  • 6.3.1. Conservative surgery
  • 6.3.2. Radical resection

7. Aggressive Fibromatosis Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Pharmacies
• 7.4. Retail Pharmacies

8. Aggressive Fibromatosis Market, by End User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals
• 8.4. Research & Academic Institutes
• 8.5. Specialty Clinics

9. Americas Aggressive Fibromatosis Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Aggressive Fibromatosis Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Aggressive Fibromatosis Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. European Medicines Agency validates SpringWorks Therapeutics' application for nirogacestat, a groundbreaking treatment for desmoid tumors, following phase 3 DeFi trial results
  • 12.3.2. SpringWorks Therapeutics' nirogacestat MAA accepted by EMA, paving the way for first EU-approved therapy for desmoid tumors, showcasing significant clinical benefits from Phase 3 trial outcomes
  • 12.3.3. Immunome acquires Phase 3 gamma secretase inhibitor AL102 from Ayala for $50M to enhance cancer therapy portfolio and clinical outcomes
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4D Molecular Therapeutics
• 2. AbbVie Inc.
• 3. Amgen Inc.
• 4. AstraZeneca plc
• 5. Aurinia Pharmaceuticals Inc.
• 6. Bayer AG
• 7. Bioporto Diagnostics A/S
• 8. Boston Scientific Corporation
• 9. Celgene Corporation (a Bristol-Myers Squibb Company)
• 10. Eli Lilly and Company
• 11. Epizyme, Inc.
• 12. Exelixis, Inc.
• 13. GlaxoSmithKline plc
• 14. Hoffmann-La Roche Ltd.
• 15. Infinity Pharmaceuticals, Inc.
• 16. Johnson & Johnson Service, Inc.
• 17. Medtronic plc
• 18. Merck & Co., Inc.
• 19. Novartis AG
• 20. Oncoheroes Biosciences Inc.
• 21. Pfizer Inc.
• 22. Sanofi S.A.
• 23. SpringWorks Therapeutics, Inc.
• 24. Takeda Pharmaceutical Company Limited
• 25. Teva Pharmaceutical Industries Ltd.